financetom
Business
financetom
/
Business
/
Update: Microsoft Fiscal Q1 EPS, Sales Increase; Shares Drop Premarket Amid Focus on Azure Growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Microsoft Fiscal Q1 EPS, Sales Increase; Shares Drop Premarket Amid Focus on Azure Growth
Nov 3, 2024 3:29 PM

05:55 AM EDT, 10/31/2024 (MT Newswires) -- (Updates with stock move and analyst comments in the headline and the last three paragraphs.)

Microsoft ( MSFT ) reported fiscal Q1 earnings late Wednesday of $3.30 per diluted share, up from $2.99 a year earlier.

Analysts polled by Capital IQ expected $3.11.

Revenue for the quarter that ended Sept. 30 was $65.59 billion, up from $56.52 billion a year earlier.

Analysts surveyed by Capital IQ expected $64.56 billion.

Azure revenue grew 34%, slightly above the company's expectations of 33%, according to a note from Truist Securities early Thursday. "However, management noted the better-than-expected result was due to the small benefit from in-period revenue recognition."

Azure growth included roughly 12 points from AI services, similar to last quarter, as per the Truist research note. Demand continues to be higher than available capacity at the company, which expects a "re-acceleration" in H2, 2025, as capital investments will increase the available AI capacity to serve more of the growing demand.

Microsoft ( MSFT ) shares were 3.8% lower in premarket activity Thursday.

Price: 416.41, Change: -16.12, Percent Change: -3.73

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck Starts Phase 3 Trial of Dengue Vaccine
Merck Starts Phase 3 Trial of Dengue Vaccine
Jun 12, 2025
07:18 AM EDT, 06/12/2025 (MT Newswires) -- Merck & Co. ( MRK ) said Thursday that it initiated the MOBILIZE-1 phase 3 clinical trial evaluating V181 for the prevention of dengue. The company has started recruitment for the study, with the first participants now enrolling in Singapore. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH
Novartis Reports 'Significant' Improvements in Study of Fabhalta to Treat PNH
Jun 12, 2025
07:15 AM EDT, 06/12/2025 (MT Newswires) -- Novartis ( NVS ) said Thursday that its phase 3b study of Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria, or PNH, showed statistically significant and clinically meaningful improvements in hemoglobin levels. The trial enrolled 52 patients who received Fabhalta for 24 weeks and the primary endpoint was change from baseline hemoglobin levels,...
Underlying Details of Canada's Unemployment Data Are A Bit Worrying, Says BMO
Underlying Details of Canada's Unemployment Data Are A Bit Worrying, Says BMO
Jun 12, 2025
07:09 AM EDT, 06/12/2025 (MT Newswires) -- The May employment figures for Canada were welcomed with a sigh of relief from markets, as they weren't nearly as weak as expected, said Bank of Montreal (BMO). Some parts of the report were encouraging, with big increases in full-time and private sector employment. Unfortunately, it wasn't all good news, noted the bank....
Copyright 2023-2026 - www.financetom.com All Rights Reserved